| Qian Niu,Jiamin Liu,Xiaoxiao Luo,Beibei Su,Xianglin Yuan. Future of targeted therapy for gastrointestinal cancer: Claudin 18.2. Oncol Transl Med, 2021, 7: 102-107. |
| 胃肠道肿瘤精准药物靶向的未来：Claudin 18.2 |
| Future of targeted therapy for gastrointestinal cancer: Claudin 18.2 |
| Received:November 16, 2020 Revised:June 22, 2021 |
| DOI：10.1007/s10330-020-0470-0 |
| 中文关键词: 胃肠道肿瘤；Claudin18.2；靶向治疗；IMAB362；CAR T治疗 |
| 英文关键词: gastrointestinal cancer; claudin 18.2 (CLDN18.2); targeted therapy; ideal monoclonal antibody 362 (IMAB362); chimeric antigen receptor (CAR) T cells treatment |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Qian Niu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | 645020547@qq.com | | Jiamin Liu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Xiaoxiao Luo | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Beibei Su | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | | | Xianglin Yuan* | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology | xlyuan1020@163.com |
|
| Hits: 5679 |
| Download times: 7352 |
| 中文摘要: |
| 目的：胃肠道肿瘤的治疗一直是研究的热点，靶向治疗受到越来越多的关注。但是当前，靶向治疗在胃癌中的疗效并不理想，发现新的靶点是至关重要的。
结果：Claudin18.2(CLDN18.2)是Claudin家族的成员,它属于紧密连接蛋白家族，控制层细胞之间的分子流动。目前的许多研究对CLDN18.2的表达进行了探讨。近年来，对CLDN18.2理想单克隆抗体(IMAB)362的靶向治疗进行了大量的研究，在最新的研究中，CLDN18.2特异性嵌合抗原受体t(CART)治疗已被用于胃癌和胰腺癌等CLDN18.2阳性的肿瘤。到现在越来越多的研究把目光放在了CLDN18.2这个靶点上。
总结：CLDN18.2是未来胃癌精准靶向治疗的新前景，为胃癌患者的治疗提供了新的希望。在这篇综述中，我们将重点介绍CLDN18.2的研究进展。 |
| 英文摘要: |
| The treatment of gastrointestinal cancer has always been a crucial research area, and targeted therapy
has been receiving increasing attention. At present, the effect of targeted therapy is unsatisfactory for
gastric cancer. Thus, the discovery of new targets is crucial. Claudin 18.2 (CLDN18.2), a member of the
claudin family, belongs to the tight junction protein family that controls the flow of molecules between
cell layers. CLDN18.2 expression has been discussed in many studies. In recent years, there have been
many studies on targeted therapy with CLDN18.2-ideal monoclonal antibody 362. Furthermore, CLDN18.2-
specific chimeric antigen receptor T therapy has been used for CLDN18.2-positive tumors, such as gastric
and pancreatic cancers. Considerable research has been focused on CLDN18.2. CLDN18.2, a newly
discovered marker for precise targeted therapy of gastric cancer, could offer new hope for the treatment of
gastric cancer. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|